Shares of Nuvation Bio (NUVB) jumped 13.4% to $5.35 on Thursday, extending a rally that began after CEO David Hung and CFO Philippe Sauvage delivered a fireside chat at the Jefferies Global Healthcare Conference on June 3. The presentation, held at 9:55 a.m. ET in New York, featured both executives discussing the company's outlook. No new data or filings accompanied the event — meaning investor enthusiasm is being driven purely by management's tone and confidence, a fragile basis for a stock that has swung violently this year.
Over 600 Patients on Its Lung Cancer Drug — and the Ramp Is Key. Since launching in late June 2025, over 600 patients have started on IBTROZI, Nuvation's approved therapy for a rare form of lung cancer called ROS1-positive NSCLC.
In Q1 2026, the drug generated $18.5 million in net product revenue, with the majority of roughly 200 new patients being first-line — meaning they chose IBTROZI before trying anything else. That first-line adoption is critical because it signals doctors view the drug as a go-to treatment, not a backup.
A $83 Million Quarter Hides a One-Time Windfall. Nuvation swung to $5.4 million in net income after a $53.2 million loss a year earlier, with total revenue hitting $83.2 million — but $64.7 million of that came from collaboration and license deals, largely a one-time Eisai upfront payment. Strip that out, and the company's recurring commercial revenue is still modest relative to its approximately $1.73 billion market cap.
Wall Street Sees Much Higher — but the Stock Has Been Crushed Before. Ten analysts polled by S&P Global give NUVB a "Strong Buy" consensus with an average price target of $12.33, implying roughly 130% upside from today's price. Yet the stock cratered 25% in early March on commercialization fears. The company holds $533.7 million in cash, giving it years of runway, but its accumulated deficit sits at roughly $1.11 billion.
Pipeline Bets Add Promise — and Risk. In March, the European Medicines Agency accepted a marketing application for its lung cancer drug, following a standard review timeline.
Nuvation also acquired global rights to safusidenib, an experimental brain-cancer drug, from Daiichi Sankyo. Both expand the company's future potential but also its spending obligations — R&D costs already hit $35 million last quarter. At $5.35, investors are betting the conference optimism translates into sustained prescription growth. The next quarterly report will show whether that faith is earned.